|
|
April 27, 2011
Dextran-Based Amorphous Dispersions as a Platform Technology in Preclinical Screening for Inhaled Dry Powders |
SPEAKERS FOR THIS EVENT: 
Dan Dobry, Vice President Engineering, Bend Research Inc. 
Dr. David T. Vodak, Vice President Chemistry, Bend Research Inc. |
|
Dextran-Based Amorphous Dispersions as a Platform Technology in Preclinical Screening for Inhaled Dry Powders
In early preclinical evaluation, the supply and availability of an appropriate form of the active pharmaceutical ingredient often limits the options for delivery and proof-of-concept in preclinical models.
Amorphous dispersion technology is ideal for early screening work because of its applicability to compounds with a broad range of properties, suitability for small‑scale use, and amenability to particle engineering using the spray-drying process.
This webinar will discuss using amorphous dispersions as a platform technology to rapidly formulate compounds as respirable dry powders for preclinical evaluation. Dextran 10 will be discussed as an exemplary dispersion excipient with optimal physical properties, including a high glass-transition temperature even at elevated relative humidities. The spray-drying process will be discussed, including the use of custom equipment designed to improve collection efficiency and yield across a wide range of scales (from 100 mg to 1 kg).
Several case studies will be presented, including in vitro and in vivo data, demonstrating that amorphous dispersions represent a broadly applicable, efficient approach to generate aerosol dry powders.
|
| THIS PROGRAM IS INTENDED FOR: |
|
Pre-Formulators for Inhalation Products and others interested in Inhalation
|
|
|
Dan Dobry, Vice President Engineering, Bend Research Inc.
Dan Dobry is the Vice President of Engineering at Bend Research Inc. In addition to business development and client relationship management, Mr. Dobry’s responsibilities include managing the process engineering group, which focuses on formulation and process engineering for novel drug‑delivery technologies.
Mr. Dobry has also been a key contributor to the development of Bend Research's spray‑dried dispersion (SDD) technology and has worked in the areas of formulation, process design, scale‑up, and technology transfer from preclinical screening through commercial‑scale manufacture.
Mr. Dobry holds a bachelor’s degree in chemical engineering from Oregon State University. He also holds two U.S. patents. He has worked for Bend Research since 1998. |
 |
Dr. David T. Vodak, Vice President Chemistry, Bend Research Inc.
Dr. Vodak is Vice President of Chemistry at Bend Research Inc. and has been with the company since 2004. His past positions have included Director of Research and Director of Physical and Biological Sciences.
Dr. Vodak’s areas of expertise at Bend Research include the research and development of novel pharmaceutical drug-delivery systems with a focus on the delivery of low-solubility compounds and on a pulmonary platform based on spray-dried engineered particles. His other research has centered on the characterization and investigation of physical properties, stability, and solubility of spray‑dried dispersions (SDDs) and on spray‑layered dispersions (SLDs).
Dr. Vodak holds a Ph.D. in materials chemistry from the University of Michigan and a B.A. in chemistry from Willamette University. He is a member of the American Chemical Society and the American Association of Pharmaceutical Scientists, and he holds three patent applications. |
| OUR XTALKS PARTNER FOR THIS EVENT: |
|
|
|
For more than 30 years, Bend Research has worked with clients to create value by advancing new medicines and to solve their most difficult scientific and technical problems. This success is based on the company’s ability to develop, advance, and commercialize pharmaceutical technologies. The firm’s innovative drug-delivery solutions grow from a solid base of scientific and engineering fundamental understanding.
Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical-trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through commercialization. Bend Research currently works with more than 60 pharmaceutical and biotechnology clients worldwide. The company has more than 195 employees based in four state-of-the-art facilities in Bend, Oregon, USA.
For more information about Bend Research and its formulation and manufacturing capabilities, please contact Dana Settell via email at Dana.Settell@bendres.com or phone 541-382-4100. |
| |